Log in

Relevant bibliographies by topics / Pidotimod

Contents

Journal articles

Academic literature on the topic 'Pidotimod'

Author: Grafiati

Published: 9 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pidotimod.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pidotimod"

1

Baghel, Madhuri, Meenakshi Bharkatiya, Falguni Tandel, and Sadhana J. Rajput. "Isolation and Characterization of Novel Degradation Product of Pidotimod." Asian Journal of Chemistry 34, no. 9 (2022): 2386–92. http://dx.doi.org/10.14233/ajchem.2022.23878.

Full text

Abstract:

A synthetic dipeptide, pidotimod (3-L-pyroglutamyl-L-thiaziolidine-4-carboxylic acid, PTD) is an immunomodulator and it possesses anti-infective activity against variety of infections. The objective of this study was to explore into and identify pidotimod’s major degradation product. Pidotimod was degraded in ICH prescribed stress conditions. pidotimod was degraded 90% in 1.0 N NaOH at 80 ºC for 6 h and the degradation product (DP2) was determined using HPLC. The HPLC method was used to separate the primary and subsidiary degradation products and carried out on a C18 column with a mobile phase

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Pidotimod." Reactions Weekly &NA;, no. 1224 (2008): 23. http://dx.doi.org/10.2165/00128415-200812240-00067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Baghel, Madhuri, Sangeeta Patil, Mukesh Sharma, et al. "Degradation Kinetic Study and Mechanistic Interpretation of Hydrolysis of Pidotimod by LC-MS/MS: A QbD Assisted Stability Indicating Method Development." Asian Journal of Chemistry 34, no. 11 (2022): 2797–805. http://dx.doi.org/10.14233/ajchem.2022.23796.

Full text

Abstract:

The stability of pidotimod was investigated in this study under ICH-recommended stress degradation conditions. To explore the degradation kinetics of pidotimod, a QbD assisted stability indicating assay method was designed and validated according to ICH Q2 (R1) guidelines. The impacts of hydrogen and hydroxide ions were explored, with a focus on the kinetics of pidotimod hydrolytic degradation to identify the rate laws, which were parameterized using linear regression analysis. The degradation product (DP2) was formed as a major degradation product of hydrolysis. Four known and one unknown deg

APA, Harvard, Vancouver, ISO, and other styles

4

Ucciferri, Claudio, Katia Falasca, Marcella Reale, et al. "Pidotimod and Immunological Activation in Individuals Infected with HIV." Current HIV Research 19, no. 3 (2021): 260–68. http://dx.doi.org/10.2174/1570162x18666210111102046.

Full text

Abstract:

Background: The improvements in HIV infection therapy and the large availability of antiretroviral drugs have led to an increased survival among HIV infected people, and simultaneously to a raised morbidity and mortality due to not-AIDS-related events in this group compared to the general population. An increased systemic inflammation and a persistent immune activation play a pivotal role in determining high rates of non-AIDS comorbidities. In the last years, many natural or synthetic immunomodulatory molecules acting by different mechanisms have been conceived. Pidotimod is a synthetic dipept

APA, Harvard, Vancouver, ISO, and other styles

5

Riboldi, P., M. Gerosa, and P. L. Meroni. "Pidotimod: A Reappraisal." International Journal of Immunopathology and Pharmacology 22, no. 2 (2009): 255–62. http://dx.doi.org/10.1177/039463200902200201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Acharya, T. C., Kundan Nivangune, Snehal Muchhala, and Rishi Jain. "Effectiveness and safety of pidotimod in recurrent respiratory infections in children: a pilot study." International Journal of Contemporary Pediatrics 6, no. 5 (2019): 2012. http://dx.doi.org/10.18203/2349-3291.ijcp20193715.

Full text

Abstract:

Background: Recurrent respiratory infections (RRIs) are common in children especially in age 1 to 6 years. Pidotimod, an immunostimulant has been found to lower the recurrences of RRIs and improve the quality of life. The Objective of this study was to assess the efficacy and safety of pidotimod in children with recurrent respiratory infections (RRIs).Methods: In this single-centre, prospective, observational study, children aged 2 to 15 years diagnosed with RRIs were included. RRIs were defined as occurrence of 3 or more episodes of acute respiratory infections (ARIs) or more than 15 days of

APA, Harvard, Vancouver, ISO, and other styles

7

Ucciferri, Claudio, Alessandro Di Gasbarro, Paola Borrelli, Marta Di Nicola, Jacopo Vecchiet, and Katia Falasca. "New Therapeutic Options in Mild Moderate COVID-19 Outpatients." Microorganisms 10, no. 11 (2022): 2131. http://dx.doi.org/10.3390/microorganisms10112131.

Full text

Abstract:

Background: In recent years, the therapeutic options for COVID have significantly improved; however, the therapies are expensive with restricted access to drugs, and expeditious and difficult to manage at home. We investigated the effect of pidotimod in preventing hospitalization in patients with mild-moderate COVID-19. Methods: A total of 1231 patients between January and June 2021 were screened. A total of 184 patients with mild-moderate COVID-19 were enrolled and divided into two groups: group-A (97) had undergone therapy with pidotimod 800 mg bid for 7–10 days and group-B (87) had other th

APA, Harvard, Vancouver, ISO, and other styles

8

Miranda Ojeda, Rául, Raúl Enrique Ávila Yáñez, Dulce Lucero Uriostegui Cordero, et al. "Pidotimod for Covid-19." Medicina e Investigación Universidad Autónoma del Estado de México 10, no. 1 (2022): 77. http://dx.doi.org/10.36677/medicinainvestigacion.v10i1.18779.

Full text

Abstract:

Covid-19 was the third leading cause of death in all of 2020, but in December 2020 and the beginning of 2021, the disease suddenly spiked and briefly became the number one cause of death in the United States (u.s.), particularly among those aged 35 years or older even though as of June 30, 2021, about 66% of adults in the u.s. have received at least one Covid-19 vaccine dose. At present, there is no drug to treat Covid-19 that can reduce the morbidity and mortality significantly, which has brought great panic to the society and scientific community. Antiviral agents and immune-modulating treat

APA, Harvard, Vancouver, ISO, and other styles

9

Ucciferri, Claudio, Antonio Auricchio, Jacopo Vecchiet, and Katia Falasca. "Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation." Mediterranean Journal of Hematology and Infectious Diseases 14, no. 1 (2022): e2022023. http://dx.doi.org/10.4084/mjhid.2022.023.

Full text

Abstract:

Background and objectives: A new pandemic has emerged across the world:Covid-19. Covid-19 has affected hundreds of millions of people globally. To stop the spread of the virus and gain a mass immunity several vaccines have been developed. BNT162b2-mRNA-vaccine has been shown to be largely effective and is widely administered. However the vaccine is not free from adverse events that could discourage vaccination in many people. The aim was evaluated adverse effect and immunological effect after second dose of BNT162b2-mRNA-vaccine in a healthcare population that take Pidotimod versus control sub

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Pidotimod enters its first market." Inpharma Weekly &NA;, no. 879 (1993): 23. http://dx.doi.org/10.2165/00128413-199308790-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!